Originally Aired: May 19, 2022
Time: 9:00 am PT, 12:00 pm ET, 18:00 CET

Single-cell RNA-Seq has transformed our understanding of complex cellular systems and the tumor microenvironment (TME). Recent studies have shown the intricate influence the TME has over developing cancer cells and how a greater understanding of this extensive network of cells and biomolecules can shape therapeutic drug selection. The integration of this cutting-edge genomic research into the clinical arena is paramount to advancing the goals of precision medicine and ultimately improving the outcome for patients.

In this GEN webinar, our distinguished speaker, Dr. Asaf Rotem, will tell us about his current work at the Center for Single-Cell Studies within AstraZeneca Oncology, which performs unbiased profiling of thousands of single cells from clinical specimens, including analyses of open chromatin, immune profiling, and cell surface proteins, integrated with RNA expression. Additionally, Dr. Rotem will explain how he and his colleagues utilize single-cell RNA-seq to study the TME upon pharmacological pressure. Finally, Dr. Rotem will detail the current study’s fascinating results, which showed a possible resistance mechanism to an AstraZeneca drug and the unique response of cells to an AstraZeneca drug combination, especially in subtypes of tumor cells.

A live Q&A followed the presentation, offering a chance to pose questions to our expert panelist.

Asaf Rotem
Asaf Rotem, PhD
Sr. Director, Translational Medicine
Lead, Center for Single Cell Studies
Oncology R&D, AstraZeneca